mRNA‐based Vaccines Targeting the T‐cell Epitope‐rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust Anti‐Tumor Immunity in Mice
Abstract: Epstein‐Barr virus (EBV) is associated with various malignancies and infects >90% of the global population. EBV latent proteins are expressed in numerous EBV‐associated cancers and contribute to carcinogenesis, making them critical therapeutic targets for these cancers. Thus, this study aims to develop mRNA‐based therapeutic vaccines that express the T‐cell‐epitope‐rich domain of truncated latent proteins of EBV, including truncatedlatent membrane protein 2A (Trunc‐LMP2A), truncated EBV nuclear antigen 1 (Trunc‐EBNA1), and Trunc‐EBNA3A. The vaccines effectively activate both cellular and humoral immunity in mice and show promising results in suppressing tumor progression and improving survival time in tumor‐bearing mice. Furthermore, it is observed that the truncated forms of the antigens, Trunc‐LMP2A, Trunc‐EBNA1, and Trunc‐EBNA3A, are more effective than full‐length antigens in activating antigen‐specific immune responses. In summary, the findings demonstrate the effectiveness of mRNA‐based therapeutic vaccines targeting the T‐cell‐epitope‐rich domain of EBV latent proteins and providing new treatment options for EBV‐associated cancers.
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
mRNA‐based Vaccines Targeting the T‐cell Epitope‐rich Domain of Epstein Barr Virus Latent Proteins Elicit Robust Anti‐Tumor Immunity in Mice ; day:27 ; month:10 ; year:2023 ; extent:15
Advanced science ; (27.10.2023) (gesamt 15)
- Creator
-
Zhao, Ge‐Xin
Bu, Guo‐Long
Liu, Gang‐Feng
Kong, Xiang‐Wei
Sun, Cong
Li, Zi‐Qian
Dai, Dan‐Ling
Sun, Hai‐Xia
Kang, Yin‐Feng
Feng, Guo‐Kai
Zhong, Qian
Zeng, Mu‐Sheng
- DOI
-
10.1002/advs.202302116
- URN
-
urn:nbn:de:101:1-2023102815341629883618
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:51 AM CEST
Data provider
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Zhao, Ge‐Xin
- Bu, Guo‐Long
- Liu, Gang‐Feng
- Kong, Xiang‐Wei
- Sun, Cong
- Li, Zi‐Qian
- Dai, Dan‐Ling
- Sun, Hai‐Xia
- Kang, Yin‐Feng
- Feng, Guo‐Kai
- Zhong, Qian
- Zeng, Mu‐Sheng
Other Objects (12)
Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines
Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity
Epitope-based vaccines: SARS – a model
Development of Epstein-Barr virus vaccines
New approaches to in silico design of epitope-based vaccines
NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy
Urgency and necessity of Epstein-Barr virus prophylactic vaccines
Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines
Developing anti-tumor vaccines : antigens and antigen-presenting cells
Predicting population coverage of T-cell epitope-based diagnostics and vaccines
Multi-epitope peptide vaccines targeting dengue virus serotype 2 created via immunoinformatic analysis
Selected anti-tumor vaccines merit a place in multimodal tumor therapies
Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines
Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity
Epitope-based vaccines: SARS – a model
Development of Epstein-Barr virus vaccines
New approaches to in silico design of epitope-based vaccines
NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy
Urgency and necessity of Epstein-Barr virus prophylactic vaccines
Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines
Developing anti-tumor vaccines : antigens and antigen-presenting cells
Predicting population coverage of T-cell epitope-based diagnostics and vaccines
Multi-epitope peptide vaccines targeting dengue virus serotype 2 created via immunoinformatic analysis
Selected anti-tumor vaccines merit a place in multimodal tumor therapies
Heterovalent Glycodendrimers as Epitope Carriers for Antitumor Synthetic Vaccines
Whole-cell tumor vaccines desialylated to uncover tumor antigenic Gal/GalNAc epitopes elicit anti-tumor immunity
Epitope-based vaccines: SARS – a model
Development of Epstein-Barr virus vaccines
New approaches to in silico design of epitope-based vaccines
NitraTh epitope-based neoantigen vaccines for effective tumor immunotherapy
Urgency and necessity of Epstein-Barr virus prophylactic vaccines
Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines
Developing anti-tumor vaccines : antigens and antigen-presenting cells
Predicting population coverage of T-cell epitope-based diagnostics and vaccines
Multi-epitope peptide vaccines targeting dengue virus serotype 2 created via immunoinformatic analysis